Genexpath was created in 2020 in Rouen, France. It develops, produces and markets innovative products resulting from academic research.

Our mission

Nowadays, the diagnosis of rare cancers is expensive.

Genexpath aims to improve the characterization of cancers through innovative approaches in molecular biology, artificial intelligence and bioinformatics.

Since its creation, Genexpath has sought to make its products usable for diagnosis to molecular biology laboratories and anatomopathology departments and to offer turnkey solutions from the bench to the bioinformatics analysis of data.

The stakes are crucial: there can be no optimal treatment without a precise diagnosis.


The research team of Henri Becquerel Cancer center (Inserm U1245) led by Professor Fabrice Jardin has been working for several years in collaboration with other institutions to develop solutions for classifying lymphomas and detecting fusion transcripts in various pathologies and in particular sarcomas.

Genexpath was created in 2020 in Rouen in Normandy to industrialize and market the products resulting from this work. It is directed by Juliette Renauld.

Genexpath is the logical continuation of this work that the research team wanted to see offered to as many as possible to facilitate and make diagnoses more reliable, at the best price. The production and quality control of Genexpath products are carried out in the Rouen premises.


LymphoSign test and SarcomaFusion test Both are based on an innovative technique that has been the subject of several publications in scientific journals with a high impact factor and has been the source of four patent applications. The technique has already been well proven.

These kits are used on tumoral RNA taken by biopsy from the patient. The innovation lies in the fact that the amount of RNA required is very low. For sarcoma, a needle biopsy, which is less invasive, is sufficient to allow the fusion transcripts detection.

Genexpath kits allow much faster and much cheaper analysis than more traditional methods.

Finally, the tests showed that it was possible to detect cases that remained undetected by conventional techniques.